About the Company
invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NVTA News
Law firm Kirkland conflicted in Invitae bankruptcy, DOJ watchdog says
The U.S. Department of Justice's bankruptcy watchdog said on Monday that genetic test maker Invitae Corp should not be ...
DOJ Bankruptcy Unit Opposes Invitae’s Bid to Hire Kirkland
Kirkland & Ellis LLP can’t represent genetic testing company Invitae Corp. in its Chapter 11 case because the law firm has a ...
Parkinson’s, MS drug company seeks sale in Chapter 11 bankruptcy
Bankruptcy filings in the healthcare sector rose significantly over the last three years, rising from 25 in 2021 to 46 in ...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society ...
Trump Media Advises ‘Long-Term’ Investors on Thwarting Shorts
Donald Trump’s social media company, whose meteoric stock gains made the former president billions on paper before a rapid selloff wiped out more than two-thirds of the advance, took the unusual step ...
Cathie Wood's ARK Makes Bold Moves in Q1 2024, Coinbase Global Inc Sees Major Reduction
ARK Investment Management's Latest 13F Filing Highlights Key Strategic Changes. Cathie Wood, the visionary founder of ARK ...
Here's Why Greenbrier Companies (GBX) Fell More Than Broader Market
The latest trading session saw Greenbrier Companies (GBX) ending at $51.22, denoting a -1.69% adjustment from its last day's close. This change lagged the S&P 500's daily loss of 0.2%. Elsewhere, the ...
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. Click ...
Rare Disease Genetic Testing Market To Attain USD 3,051.6 Million By 2032
According to Market.us, the Global Rare Disease Genetic Testing Market is projected to reach approximately USD 3,051.6 ...
Loading the latest forecasts...